{"id":"NCT00654927","sponsor":"Acorda Therapeutics","briefTitle":"Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis","officialTitle":"Phase 3 Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2003-11","primaryCompletion":"2011-01","completion":"2011-04","firstPosted":"2008-04-09","resultsPosted":"2012-02-29","lastUpdate":"2012-03-02"},"enrollment":177,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Sclerosis"],"interventions":[{"type":"DRUG","name":"Fampridine-SR b.i.d. (Twice Daily)","otherNames":["4-aminopyridine"]}],"arms":[],"summary":"The purpose of this study is to evaluate the long-term safety, tolerability and activity of Fampridine-SR in subjects with multiple sclerosis who have previously participated in either an Acorda Therapeutics or an Elan Corporation sponsored protocol. Subjects are eligible regardless of whether they received active drug or placebo during their participation in the previous study.","primaryOutcome":{"measure":"Summary of Treatment Emergent Adverse Events (TEAE).","timeFrame":"over 7 years (2004-2011)","effectByArm":[{"arm":"Fampridine-SR b.i.d.","deltaMin":176,"sd":99.4}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":11},"locations":{"siteCount":22,"countries":["United States","Canada"]},"refs":{"pmids":[],"seeAlso":["http://www.acorda.com/clinical.asp"]},"adverseEventsSummary":{"seriousAny":{"events":65,"n":177},"commonTop":["Urinary Tract Infection","Fall","Insomnia","Muscular Weakness","Multiple Sclerosis Relapse"]}}